In conclusion, this retrospective study suggests that serum sPD-L1 levels may be associated with OS in NSCLC patients treated with anti-PD-1/anti-PD-L1 therapies within a 2-year follow-up period. This evidence concerns the gene SPDL1 and non-small cell lung carcinoma.